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Abstract
Background: Spinal Muscular Atrophy (SMA) is the leading genetic cause of infantile death. It is
caused by the loss of functional Survival Motor Neuron 1 (SMN1). There is a nearly identical copy
gene, SMN2, but it is unable to rescue from disease due to an alternative splicing event that excises
a necessary exon (exon 7) from the majority of SMN2-derived transcripts. While SMNΔ7 protein
has severely reduced functionality, the exon 7 sequences may not be specifically required for all
activities. Therefore, aminoglycoside antibiotics previously shown to suppress stop codon
recognition and promote translation read-through have been examined to increase the length of
the SMNΔ7 C-terminus.
Results:  Here we demonstrate that subcutaneous-administration of a read-through inducing
compound (TC007) to an intermediate SMA model (Smn-/-; SMN2+/+; SMNΔ7) had beneficial
effects on muscle fiber size and gross motor function.
Conclusion:  Delivery of the read-through inducing compound TC007 reduces the disease-
associated phenotype in SMA mice, however, does not significantly extend survival.
Background
Spinal Muscular Atrophy (SMA) is the leading genetic
cause of infantile death. The clinical categorization of
SMA is based upon disease severity and age of onset [1].
SMA results from the lack of a functional copy of the Sur-
vival Motor Neuron 1 (SMN1) gene [2]. There is a nearly
identical copy gene, SMN2, found only in humans [3].
SMN2 does not fully compensate for the loss of SMN1,
due to an alternative splicing event induced by a non-pol-
ymorphic C to T transition within exon 7 [4,5]. Alterna-
tive pre-mRNA splicing, therefore, results in the majority
of SMN2 transcripts excluding exon 7 (SMNΔ7), encoding
a less stable protein product compared to full-length SMN
[6,7]. Loss of full-length SMN protein leads to the death
of α-motor neurons, however, it is unclear why motor
neurons are particularly susceptible to low levels of this
ubiquitously expressed protein. However, two hypotheses
suggest that axonal RNA transport and/or snRNP biogen-
esis underlie the SMA-associated activity [8].
Since the lack of SMN exon 7 leads to SMA development,
this sequence is clearly important. There is a cytoplasmic
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localization signal within SMN exon 7 (QNQKE) that can
transport SMN exons 1-6 and other heterologous nuclear
proteins to the cytoplasm [9]. However, heterologous
sequences can mediate proper SMN localization in several
cellular contexts in vitro. In addition, heterologous
sequences can also partially restore functionality in cell-
based assays, such as protein stability, snRNP assembly
and neurite extension assays [10-13]. For these reasons,
aminoglycosides have been examined in SMA for their
ability to induce translational "read-through." These com-
pounds are presumed to inhibit the recognition of the
endogenous SMNΔ7 translational stop codon, located
four amino acids into exon 8. "Read-through" of the stop
codon would thereby allow the incorporation of a C-ter-
minal extension of an additional five amino acids [10-
13]. Treating Type I primary SMA patient fibroblasts
(3813s) or SMA iPS-derived neuronal cultures with
aminoglycosides was shown to increase SMN protein
[10,13,14]. When delivered via intra-peritoneal injection,
treatment with the aminoglycoside G418 in a SMA mouse
model increased gross motor function at select time
points [10]. Additionally, direct injection of TC007, a
novel aminoglycoside, into the central nervous system
extends life span approximately 30% and elevates SMN
protein in the brain and spinal cord [15]. To begin to
examine a less invasive means of delivery, we have exam-
ined alternative routes of delivery for TC007. Here we
demonstrate that subcutaneous administration of TC007,
while not extending survival, results in improved molecu-
lar and cellular aspects of the SMA phenotype, as well as
benefits in gross motor function in a SMA mouse model.
Results and discussion
Subcutaneous dosing of SMA mice with TC007 
significantly increases gross motor function, but not 
lifespan
Based on previous in vivo examinations of aminoglyco-
sides and stop codon readthrough [16], we administered
subcutaneous doses of TC007 [17] at 30 mg/kg daily from
post-natal day (p) 2 to 15 to the well-characterized Δ7
SMA model (Smn-/-;  SMN2+/+; SMNΔ7) [18]. TC007
treated mice (n = 16) lived approximately 16% longer
(from an average of 15.75 ± 1.315 to 18.25 ± 0.7555 days)
than vehicle treated mice (n = 16), although this differ-
ence did not reach statistical significance (Figure 1). The
aminoglycosides appeared to prevent the death at a
younger age, resulting in larger numbers of mice dying
later (median lifespan of vehicle-treated mice 17.5 days
versus a median of 19 days for TC007-treated). However,
the longest life spans were similar in the vehicle and
TC007-treated mice. Moreover not all aminoglycosides
that increase SMN levels confer the same survival effect.
For example, administration of Neo002 (n = 8) [19], a
compound containing the same chemical backbone as
TC007, significantly elevated SMN levels in vitro (data not
shown), but only marginally affected lifespan (Figure 1).
Total body weight was unaffected in TC007 and Neo002
treated animals compared to vehicle treated SMA animals
(data not shown). Since SMN read-through therapies are
proposed to function in part through a stabilization of
SMNΔ7 protein, various tissues were examined for an
increase in steady-state levels of SMN protein. Therefore
brain, spinal cord and muscle of p10-treated mice were
isolated. Under these experimental conditions, we could
not detect a significant increase of SMN (Figure 2), which
may also explain the modest extension in lifespan.
TC007-treated mice, however, did exhibit increased gross
motor function. A previously quantifiable measure of
gross motor function in these SMA mice is determining
the time it takes for a pup to right itself from a prone posi-
tion, or time-to-right [20]. Not only did TC007-treated
pups right faster, but they were also able to right signifi-
cantly more often than their untreated counterparts at
mid- to end-stage of disease (Figure 3A and 3B). When the
gastrocnemius of p10 mice were examined, the fibers were
significantly larger in the TC007-treated group (Figure 4),
showing an anatomical correlation with our observed
increase in overall gross motor function.
To determine if with the increase in fiber size, an increased
survival of motor neurons was also observed, ventral horn
cells (VHCs) were examined of p10 TC007-treated and
vehicle-treated mice. While there was no increase in VHC
cell body size, there was a slight trend towards an
increased number of VHCs in treated tissues (Figure 5),
TC007-treated mice have a slightly increased average lifespan Figure 1
TC007-treated mice have a slightly increased aver-
age lifespan. Kaplan-Meyer shown of TC007-treated (solid 
black, n = 16), Vehicle-treated (PBS; dotted black, n = 16), 
and Neo002-treated (dotted-grey, n = 8) SMA mice lifespans. 
Arrows on X-axis represent the average lifespan. No signifi-
cant difference was seen between the groups.BMC Neuroscience 2009, 10:142 http://www.biomedcentral.com/1471-2202/10/142
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although statistical significance was not achieved. This
time point was chosen for histological examination due to
its correlation with the most prominent display of an
increase in gross motor function by the TC007-treated
group. The increased fiber size along with the increase
VHC numbers does provide a cellular corroboration to
the improved gross motor phenotype seen upon subcuta-
neous administration of TC007. However, more pro-
nounced improvements were likely not observed if TC007
failed to cross the blood-brain-barrier or if the compound
exhibits a short half life. As no medicinal chemistry has
been performed on TC007 to improve its drug-like quali-
ties, it is not surprising that at this early stage the com-
pound lacks properties typically associated with drugs for
CNS disorders. To date, properties such as blood-brain-
barrier permeability and pharmacokinetics have not been
examined for TC007 but will be important to analyze in
the event that TC007 or similar scaffolds move forward
toward clinical application. While it is possible that
TC007 is functioning as a general neuroprotectant, it is
more likely that SMN levels were the basis for the cellular
and gross motor activity increases. Unfortunately, the in
vivo examination of this compound did not correlate with
the in vitro activity when administered under these exper-
imental conditions [14], however, direct administration
of TC007 into the CNS by intraventricular injection did
significantly elevate SMN levels and extend life by approx-
imately 30% [15]. Clearly, moving this compound for-
No significant induction of SMN protein seen after subcutaneous TC007 administration Figure 2
No significant induction of SMN protein seen after subcutaneous TC007 administration. Representative western 
blots and quantification shown of (A) Brain, (B) Spinal cord and (C) Triceps of TC007- (black bar) or vehicle-treated (striped 
bar) SMA mice and uninjected wild-type (grey bar) mice. Actin used as a loading control. Error bars represent SEM and an "n" 
of 3 was used for each group.BMC Neuroscience 2009, 10:142 http://www.biomedcentral.com/1471-2202/10/142
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ward and making it more amenable for central nervous
system diseases will require an in depth analysis of its
pharmacokinetics and the development of medicinal
chemistry beyond these proof-of-concept experiments.
SMNΔ7 read-through benefits SMA mouse models
Translation stop codon read-through occurs at a relatively
low frequency in the presence of aminoglycosides and this
is likely true for the SMNΔ7 exon 8 stop codon based
upon its specific stop codon and the proximal sequences
flanking the stop signal [10,14]. Aminoglycoside treat-
ment likely generates a low level of SMN read-through
protein that enters into an SMN complexes with the exist-
ing full-length protein. This theory is supported by previ-
ously published data, demonstrating a small increase in
SMN-FL protein after treatment, without increasing
SMN2-transcription or altering exon 7 splicing [14]. In
vitro studies have indicated that this possible hetero-oli-
gomerization leads to an increase in the functionality of
the SMN protein [12]. While it is still possible that read-
through SMN is not as active in SMA-specific activities,
experiments such as the development of a read-through
SMA mouse would be an important step towards deter-
mining the extent of SMN read-through functionality and
whether read-through based therapeutic strategies hold
promise for SMA.
Conclusion
In conclusion, similar benefits have been reported here
for TC007 regarding a SMNΔ7 read-through therapy com-
pared to previously published work using a FDA-
approved aminoglycosides, G418 [10]. While TC007
treatment does not result in a statistically significant
extension in median lifespan, there were significant
increases in gross motor function and muscle integrity at
mid-stage of disease (p10). Extension in life span was
demonstrated when TC007 was administered directly to
the central nervous system via intracerebral ventricular
injection, suggesting that the importance in delivery strat-
egies as well as likely target tissues for SMA therapeutics
[15]. Taken together, these results demonstrate the proof-
of-concept utility of read-through compounds in SMA cell
and animal models.
Methods
Animals and drug treatment
All animal experiments were carried out in accordance
with protocols approved by the Animal Care and Use
Committee of the University of Missouri. Mice were gen-
otyped and litters excluded as previously described [21].
TC007 was initially resuspended in dH20, further diluted
in PBS, and administered by subcutaneous injection (10
μl/gram of body weight) on post-natal days 2 through 15.
PBS (vehicle) was injected as a negative control. To assess
gross motor function, righting reflex (as described in [20])
was measured starting at post-natal day 5.
Western blot analysis
Tissues were harvested at indicated times and analysis was
performed as previously described [21]. Mouse anti-SMN
(BD) was used for western at 1:1,000 and rabbit anti-actin
(Sigma) was used at 1:250.
Histology and morphometry
Spinal cords were harvested on post-natal day (p) 10 and
analysis of VHCs were performed as previously described
[21]. Gastrocnemius muscle was also harvested on p10,
TC007-treated mice have significantly increased gross motor  function than vehicle treated as measured by time-to-right  (TTR) Figure 3
TC007-treated mice have significantly increased 
gross motor function than vehicle treated as meas-
ured by time-to-right (TTR). (A) TC007-treated mice 
right faster than vehicle treated mice. Each circle (vehicle, n = 
16) or square (TC007, n = 16) represents an individual 
mouse, with the bar (solid, TC007; dotted, vehicle) demon-
strating the average. (B) More TC007-treated mice are able 
to right on average. Average percentage able to right plotted 
against day for each group. Black solid line represents 
TC007-treated group and grey dotted line represents vehi-
cle-treated. Error bars represent SEM and significant days 
indicated by: *p < 0.05 or ** p < 0.02 as determined by two-
way ANOVA.BMC Neuroscience 2009, 10:142 http://www.biomedcentral.com/1471-2202/10/142
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Gastrocnemius muscle fibers from p10 mice were significantly larger in TC007-subcutaneously treated intermediate mice Figure 4
Gastrocnemius muscle fibers from p10 mice were significantly larger in TC007-subcutaneously treated inter-
mediate mice. (A) Representative pictures of fixed and H&E stained gastrocnemius fibers from Wild-type or SMA mice 
(TC007- or vehicle-treated, respectively). (B) Graph of mean fiber area of the three groups. Significance by Student's T Test 
between TC007- or vehicle-treated mice indicated on graph (*), error bars represent SEM, and an "n" of 3 was used for each 
group.
Ventral horn cells (VHCs) trend towards increased VHC numbers between TC007- versus vehicle-treated SMA mice Figure 5
Ventral horn cells (VHCs) trend towards increased VHC numbers between TC007- versus vehicle-treated 
SMA mice. (A) Average VHC number in 14 sections of Wild-type, or vehicle- and TC007-treated p10 SMA mice. Each point 
represents an individual mouse, the horizontal line represents the average, and error bars represent SEM. (B) Representative 
pictures of fixed and cresyl violet-stained lumbar spinal cord sections from Wild-type or SMA mice (vehicle- or TC007-treated, 
respectively with an "n" of three for each group).Publish with BioMed Central    and   every 
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dissected, fixed in 4% paraformaldehyde, embedded in
paraffin, sectioned and stained with hematoxylin and
eosin stain. 200 fiber diameters were measured per sec-
tion, 15 sections per muscle.
Statistical analyses
Analysis was performed as previously described [21].
Briefly, error bars on graphs represent Standard Error of
the Mean (S.E.M.). Significance of lifespan between
TC007- and vehicle-treated mice was determined by Man-
tel-Cox test. All other indicated statistical significance was
calculated by either Student's T Test or two-way ANOVA
with a Bonferonni post hoc test of p < 0.05 or greater, as
indicated in figure legend.
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